Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
PAC481
Pancreatic cancer tissue array, set 1, contains 20 cases of pancreatic cancers and 4 cases of normal and non-malignant pancreatic tissues in duplicates with grading and TNM staging data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$298
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
TNM Classification : Pancreas carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ
T1 - Tumor limited to pancreas, 2 cm or less in greatest dimension
T2 - Tumor limited to pancreas, more than 2 cm in greatest dimension
T3 - Tumor extends directly into any of the following: duodenum, bile duct, peripancreatic tissue
T4 - Tumor extends directly into any of the following: stomach, spleen, colon, adjacent large vessels
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Regional lymph node metastasis
N1a - metastasis in a single regional lymph node
N1b - Metastasis in multiple regional lymph nodes
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
Human
24
48
1.5mm
4um
6
8
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in pancreas cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 46 | Pancreas | Normal | |||
A02 | M | 66 | Pancreas | Norma | |||
A03 | F | 58 | Pancreas | Normal | |||
A04 | F | 28 | Pancreas | Islet cell tumor | |||
A05 | F | 44 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
A06 | F | 64 | Pancreas | Adenocarcinoma | I~II | T2N0M0 | |
A07 | M | 56 | Pancreas | Adenocarcinoma | I | T2N0M0 | |
A08 | F | 49 | Pancreas | Adenocarcinoma | I | T3N0M0 | |
B01 | M | 46 | Pancreas | Normal | |||
B02 | M | 66 | Pancreas | Norma | |||
B03 | F | 58 | Pancreas | Normal | |||
B04 | F | 28 | Pancreas | Islet cell tumor | |||
B05 | F | 44 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
B06 | F | 64 | Pancreas | Adenocarcinoma | I~II | T2N0M0 | |
B07 | M | 56 | Pancreas | Adenocarcinoma | I | T2N0M0 | |
B08 | F | 49 | Pancreas | Adenocarcinoma | I | T3N0M0 | |
C01 | F | 53 | Pancreas | Adenocarcinoma | II | T2N0M0 | |
C02 | F | 49 | Pancreas | Adenocarcinoma | II | T3N1M1 | |
C03 | F | 52 | Pancreas | Adenocarcinoma | II | T4N1M1 | |
C04 | F | 42 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
C05 | M | 58 | Pancreas | Adenocarcinoma | II~III | T3N0M0 | |
C06 | F | 60 | Pancreas | Adenocarcinoma | II~III | T3N1M1 | |
C07 | F | 53 | Pancreas | Adenocarcinoma | II | T2N0M0 | |
C08 | M | 69 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
D01 | F | 53 | Pancreas | Adenocarcinoma | II | T2N0M0 | |
D02 | F | 49 | Pancreas | Adenocarcinoma | II | T3N1M1 | |
D03 | F | 52 | Pancreas | Adenocarcinoma | II | T4N1M1 | |
D04 | F | 42 | Pancreas | Adenocarcinoma | II | T3N0M0 | |
D05 | M | 58 | Pancreas | Adenocarcinoma | II~III | T3N0M0 | |
D06 | F | 60 | Pancreas | Adenocarcinoma | II~III | T3N1M1 | |
D07 | F | 53 | Pancreas | Adenocarcinoma | II | T2N0M0 | |
D08 | M | 69 | Pancreas | Adenocarcinoma | I | T3N1M0 | |
E01 | F | 40 | Pancreas | Adenocarcinoma | II | T4N0M1 | |
E02 | M | 51 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
E03 | F | 76 | Pancreas | Adenocarcinoma | III | T3N1M0 | |
E04 | F | 53 | Pancreas | Adenocarcinoma | II | T3N1M0 | |
E05 | F | 51 | Pancreas | Adenocarcinoma | III | T3N0M0 | |
E06 | F | 42 | Pancreas | Adenocarcinoma | III | T3N0M0 | |
E07 | M | 40 | Pancreas | Adenocarcinoma | II~III | T3N1M0 | |
E08 | M | 64 | Liver | Metastatic pancreatic carcinoma | |||
F01 | F | 40 | Pancreas | Adenocarcinoma | II | T4N0M1 | |
F02 | M | 51 | Pancreas | Adenocarcinoma | III | T2N0M0 | |
F03 | F | 76 | Pancreas | Adenocarcinoma | III | T3N1M0 | |
F04 | F | 53 | Pancreas | Adenocarcinoma | II | T3N1M0 | |
F05 | F | 51 | Pancreas | Adenocarcinoma | III | T3N0M0 | |
F06 | F | 42 | Pancreas | Adenocarcinoma | III | T3N0M0 | |
F07 | M | 40 | Pancreas | Adenocarcinoma | II~III | T3N1M0 | |
F08 | M | 64 | Liver | Metastatic pancreatic carcinoma | |||
null |
